Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Corvus Pharmaceuticals has initiated an underwritten public offering of $150 million in common stock and pre-funded warrants, with an additional option for underwriters to purchase up to $22.5 million more [1][2]. Group 1: Offering Details - The public offering consists of $150 million in shares of common stock and pre-funded warrants, all offered by Corvus Pharmaceuticals [1]. - The underwriters have a 30-day option to purchase an additional $22.5 million in shares at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering are expected to be used for working capital and general corporate purposes, including capital expenditures and research and development [2]. - Specific clinical trials funded by the proceeds include Phase 3 for T cell lymphoma and Phase 2 for atopic dermatitis, hidradenitis suppurativa, and asthma [2]. Group 3: Underwriters - Jefferies and Goldman Sachs & Co. LLC are the lead book-running managers for the offering, with Mizuho as the bookrunner and Ladenburg Thalmann as a co-manager [3]. Group 4: Regulatory Information - A shelf registration statement on Form S-3 was declared effective by the SEC on August 15, 2024, allowing the sale of these securities [4]. - A preliminary prospectus supplement will be filed with the SEC on January 20, 2026, and will be available on the SEC's website [4].